Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Acurx Pharmaceuticals Inc

ACXP ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.40

▼ -5.74%

Market Cap $7.35M · Vol 69.90K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$7.35M

Micro Cap

Div Yield

N/A

EPS Growth

+69.49%

YoY

RSI (14)

46.60

Momentum

Beta

-2.09

vs Market

52W High

$8.34

83.27% below

52W Low

$1.31

6.49% above

Volume

69.90K

Avg 16.04K

P/B

1.11

Price-to-book

ROE

N/A

Return on equity

Free Float

97.01%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Acurx Pharmaceuticals Inc (ACXP) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ACXP pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-9.42%

-15.45%

-28.09%

-29.19%

YTD

-43.98%

-71.30%

-95.64%

-98.54%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,966,540.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-137.98% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.11
P/FCF	N/A
EPS Growth	+69.49%
Outstanding Shares	5.27M

Technical Indicators

50-Day SMA	$1.52
200-Day SMA	$2.68
RSI (14)	46.60
Beta	-2.09
52-Week High	$8.34
52-Week Low	$1.31

Volume Today	69.90K
Avg Daily Volume (30D)	16.04K
Relative Volume	4.36x
Volatility (10D)	55.87
Volatility (30D)	64.85
Free Float	97.01%

Analyst Consensus

BUY

Current Price $1.40

Mean Target $17.00

52W Low$1.31 52W High$8.34

Current

Target

$1.31 $8.34

Current Analyst target

+1,118.64% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01184DNK2

ISINUS00510M2035

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.